Tvardi Therapeutics is trading at $1.22, up 6.1%, in pre-market on October 5 versus the supplied previous close of $1.15; no clear company-specific announcement explaining the move was identified. - The company’s latest listed press release, dated September 24, concerns preclinical ulcerative-colitis data, not a new October 5 catalyst. - Major indices are nearly flat in the supplied market context, so broader-market direction does not clearly explain the gain.